Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WASSIM SAIKALI

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1992755201
CMS profile
135266
Location
BECKLEY, WV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$240,393.22

371 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $70,450.80 97
ANI Pharmaceuticals, Inc. $60,015.98 81
Amgen Inc. $38,668.54 76
UCB, Inc. $26,941.07 57
AstraZeneca Pharmaceuticals LP $17,188.90 20
Novartis Pharmaceuticals Corporation $9,257.23 14
Mallinckrodt Hospital Products Inc. $9,179.71 7
GlaxoSmithKline, LLC. $6,073.74 6
Janssen Biotech, Inc. $2,336.32 3
GENZYME CORPORATION $97.69 1
E.R. Squibb & Sons, L.L.C. $78.70 1
PFIZER INC. $45.24 4
Radius Health, Inc. $22.39 1
Sandoz Inc. $18.65 1
Janssen Pharmaceuticals, Inc $13.17 1
Organon LLC $5.09 1

Page 8 of 8; records 351–371 of 371 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WASSIM SAIKALI

NPI 1992755201 · CMS profile ID 135266

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

BECKLEY, WV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 8 of 8; records 351–371 of 371 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1992755201?year=2025&recipient=provider&page=8#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WASSIM SAIKALI, NPI 1992755201, CMS profile ID 135266. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 8; records 351–371 of 371 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1992755201?year=2025&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). WASSIM SAIKALI, NPI 1992755201, CMS profile ID 135266. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 8; records 351–371 of 371 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1992755201?year=2025&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
WASSIM SAIKALI, NPI 1992755201, CMS profile ID 135266, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 8 of 8; records 351–371 of 371 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1992755201?year=2025&recipient=provider&page=8#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

371 matching records · $240,393.22 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 371 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 351–371 of 371.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $135.0001/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206476942 CMS
AstraZeneca Pharmaceuticals LP $688.4401/31/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1206749281 CMS
AstraZeneca Pharmaceuticals LP $25.0001/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206832301 CMS
AstraZeneca Pharmaceuticals LP $75.0001/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206998341 CMS
AstraZeneca Pharmaceuticals LP $50.0001/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207233498 CMS
ABBVIE INC. $3.0801/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204008339 CMS
Amgen Inc. $14.6101/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227255887 CMS
Amgen Inc. $649.5001/27/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226892946 CMS
UCB, Inc. $6.6001/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224627719 CMS
Amgen Inc. $18.0501/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228692834 CMS
ABBVIE INC. $3,325.0001/21/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1204008334 CMS
ABBVIE INC. $3.0801/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204008327 CMS
ANI Pharmaceuticals, Inc. $8.4201/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248609589 CMS
PFIZER INC. $14.6401/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229911025 CMS
ABBVIE INC. $3,325.0001/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1204008321 CMS
Amgen Inc. $19.4401/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228692812 CMS
GlaxoSmithKline, LLC. $98.7401/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1190705939 CMS
UCB, Inc. $6.5201/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224627717 CMS
ABBVIE INC. $2.8301/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204008315 CMS
ABBVIE INC. $5.5901/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204008309 CMS
UCB, Inc. $9.2301/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224627715 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $280,228.11 511
PY2020 $134,095.82 279
PY2021 $88,808.02 289
PY2022 $117,693.37 344
PY2023 $144,375.65 371
PY2024 $132,979.83 308
PY2025 $240,393.22 371

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,416,700.75 79
PY2024 Recipient $5,833.58 5
PY2024 Principal investigator $1,299,099.43 153
PY2023 Recipient $4,136.15 2
PY2023 Principal investigator $975,488.93 172
PY2022 Recipient $5,553.00 5
PY2022 Principal investigator $645,052.33 94
PY2021 Principal investigator $674,499.03 76
PY2020 Principal investigator $1,039,186.21 101
PY2019 Principal investigator $443,927.79 67

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

79 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $1,611.86 12/16/2025 Non-covered Recipient Entity
Rheumatology and Pulmonary Clinic
A PHASE 3 MULTICENTER OPENLABEL EXTENSION STUDY TO INVESTIGATE THE LONGTERM SAFETY TOLERABILITY AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228805246
Principal investigator 1 ABBVIE INC. $5,428.30 12/04/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202526716
Principal investigator 1 ABBVIE INC. $2,952.93 12/04/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202526718
Principal investigator 1 ABBVIE INC. $3,282.63 12/04/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202526720
Principal investigator 1 PFIZER INC. $1,953.71 11/26/2025 Non-covered Recipient Entity
Rheumatology and Pulmonary Clinic
A PHASE 3 MULTICENTER OPENLABEL EXTENSION STUDY TO INVESTIGATE THE LONGTERM SAFETY TOLERABILITY AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228818144
Principal investigator 1 ABBVIE INC. $11,816.00 11/05/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202522995
Principal investigator 1 ABBVIE INC. $2,032.80 11/04/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202521163
Principal investigator 1 ABBVIE INC. $267.15 11/04/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202521165
Principal investigator 1 UCB SA $10,935.25 10/17/2025 Non-covered Recipient Entity
Summit Rheumatology - Rheumatology And Pulmonary Clinic
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS No dispute reported 06/30/2026 1246658022
Principal investigator 1 ABBVIE INC. $3,656.83 10/09/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202514835
Principal investigator 1 ABBVIE INC. $5,657.41 10/09/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202514837
Principal investigator 1 PFIZER INC. $3,223.72 10/08/2025 Non-covered Recipient Entity
Rheumatology and Pulmonary Clinic
A PHASE 3 MULTICENTER OPENLABEL EXTENSION STUDY TO INVESTIGATE THE LONGTERM SAFETY TOLERABILITY AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228824000
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 09/24/2025 Non-covered Recipient Entity
Rheumatology And Pulmonary Clinic PLLC
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220773815
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 09/24/2025 Non-covered Recipient Entity
Rheumatology And Pulmonary Clinic PLLC
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220773817
Principal investigator 1 Boehringer Ingelheim International GmbH $511.00 09/24/2025 Non-covered Recipient Entity
Rheumatology And Pulmonary Clinic PLLC
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220773819
Principal investigator 1 Boehringer Ingelheim International GmbH $131.10 09/24/2025 Non-covered Recipient Entity
Rheumatology And Pulmonary Clinic PLLC
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220773821
Principal investigator 1 Boehringer Ingelheim International GmbH $40.56 09/24/2025 Non-covered Recipient Entity
Rheumatology And Pulmonary Clinic PLLC
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220773823
Principal investigator 1 Boehringer Ingelheim International GmbH $40.56 09/24/2025 Non-covered Recipient Entity
Rheumatology And Pulmonary Clinic PLLC
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220773825
Principal investigator 1 Boehringer Ingelheim International GmbH $40.56 09/24/2025 Non-covered Recipient Entity
Rheumatology And Pulmonary Clinic PLLC
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220773827
Principal investigator 1 Boehringer Ingelheim International GmbH $40.56 09/24/2025 Non-covered Recipient Entity
Rheumatology And Pulmonary Clinic PLLC
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220773829
Principal investigator 1 Boehringer Ingelheim International GmbH $20.00 09/24/2025 Non-covered Recipient Entity
Rheumatology And Pulmonary Clinic PLLC
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220773831
Principal investigator 1 ABBVIE INC. $5,614.76 09/03/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202507217
Principal investigator 1 ABBVIE INC. $3,529.21 09/03/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202507219
Principal investigator 1 ABBVIE INC. $1,328.95 08/05/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202502204
Principal investigator 1 ABBVIE INC. $3,224.63 08/05/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202502206
Principal investigator 1 PFIZER INC. $2,685.11 08/02/2025 Non-covered Recipient Entity
Rheumatology and Pulmonary Clinic
A PHASE 3 MULTICENTER OPENLABEL EXTENSION STUDY TO INVESTIGATE THE LONGTERM SAFETY TOLERABILITY AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228828666
Principal investigator 1 Janssen Research & Development, LLC $508.00 07/14/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175386234
Principal investigator 1 Janssen Research & Development, LLC $508.00 07/14/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175386250
Principal investigator 1 Janssen Research & Development, LLC $127.00 07/14/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175386334
Principal investigator 1 PFIZER INC. $1,611.86 07/11/2025 Non-covered Recipient Entity
Rheumatology and Pulmonary Clinic
A PHASE 3 MULTICENTER OPENLABEL EXTENSION STUDY TO INVESTIGATE THE LONGTERM SAFETY TOLERABILITY AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228828094
Principal investigator 1 Janssen Research & Development, LLC $381.00 07/07/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175386256
Principal investigator 1 Janssen Research & Development, LLC $508.00 07/07/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175386267
Principal investigator 1 Janssen Research & Development, LLC $127.00 07/07/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175386289
Principal investigator 1 Janssen Research & Development, LLC $127.00 07/07/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175386294
Principal investigator 1 Janssen Research & Development, LLC $127.00 07/07/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175386300
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 07/07/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175386328
Principal investigator 1 Janssen Research & Development, LLC $127.00 07/07/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175386339
Principal investigator 1 Janssen Research & Development, LLC $381.00 07/07/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175386345
Principal investigator 1 ABBVIE INC. $6,090.59 07/02/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202494407
Principal investigator 1 ABBVIE INC. $6,678.44 07/02/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202494409
Principal investigator 1 PFIZER INC. $1,611.86 06/26/2025 Non-covered Recipient Entity
Rheumatology and Pulmonary Clinic
A PHASE 3 MULTICENTER OPENLABEL EXTENSION STUDY TO INVESTIGATE THE LONGTERM SAFETY TOLERABILITY AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228829292
Principal investigator 1 PFIZER INC. $659.86 06/26/2025 Non-covered Recipient Entity
Rheumatology and Pulmonary Clinic
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228829342
Principal investigator 1 Janssen Research & Development, LLC $1,973.00 06/16/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175386244
Principal investigator 1 Janssen Research & Development, LLC $1,973.00 06/16/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175386262
Principal investigator 1 Janssen Research & Development, LLC $1,973.00 06/16/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175386273
Principal investigator 1 Janssen Research & Development, LLC $1,910.00 06/16/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175386278
Principal investigator 1 Janssen Research & Development, LLC $1,335.00 06/13/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175386239
Principal investigator 1 Janssen Research & Development, LLC $63.00 06/13/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175386315
Principal investigator 1 Janssen Research & Development, LLC $5,500.00 06/09/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175386307
Principal investigator 1 ABBVIE INC. $4,796.56 06/03/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202488153
Principal investigator 1 ABBVIE INC. $4,364.36 06/03/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202488155
Principal investigator 1 PFIZER INC. $5,772.36 05/30/2025 Non-covered Recipient Entity
Rheumatology and Pulmonary Clinic
A PHASE 3 MULTICENTER OPENLABEL EXTENSION STUDY TO INVESTIGATE THE LONGTERM SAFETY TOLERABILITY AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228832365
Principal investigator 1 Eli Lilly and Company $6,538.00 05/23/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187890372
Principal investigator 1 Amgen Inc. $15,596.17 05/21/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246647297
Principal investigator 1 ABBVIE INC. $4,048.21 05/06/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202482155
Principal investigator 1 ABBVIE INC. $7,938.42 05/06/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202482157
Principal investigator 1 Janssen Research & Development, LLC $2,163.00 04/28/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175386321
Principal investigator 1 ABBVIE INC. $6,473.01 04/03/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202472496
Principal investigator 1 ABBVIE INC. $8,100.00 04/03/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202473567
Principal investigator 1 ABBVIE INC. $2,000.90 04/03/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202473573
Principal investigator 1 PFIZER INC. $2,135.90 03/22/2025 Non-covered Recipient Entity
Rheumatology and Pulmonary Clinic
A PHASE 3 MULTICENTER OPENLABEL EXTENSION STUDY TO INVESTIGATE THE LONGTERM SAFETY TOLERABILITY AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228831220
Principal investigator 1 Amgen Inc. $46,269.99 03/14/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgrens Syndrome With Moderate-to-Severe Systemic Disease Activity No dispute reported 06/30/2026 1246647304
Principal investigator 1 ABBVIE INC. $7,800.07 03/06/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202457653
Principal investigator 1 ABBVIE INC. $6,520.02 03/06/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202457793
Principal investigator 1 Novartis Pharmaceuticals Corporation $543,457.12 02/18/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC, PLLC
An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment No dispute reported 06/30/2026 1190308040
Principal investigator 1 PFIZER INC. $2,669.35 02/11/2025 Non-covered Recipient Entity
Rheumatology and Pulmonary Clinic
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228827664
Principal investigator 1 PFIZER INC. $2,257.20 02/10/2025 Non-covered Recipient Entity
Rheumatology Pulmonary Clini
A PHASE 3 MULTICENTER OPENLABEL EXTENSION STUDY TO INVESTIGATE THE LONGTERM SAFETY TOLERABILITY AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228808717
Principal investigator 1 ABBVIE INC. $3,869.58 02/05/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202445047
Principal investigator 1 ABBVIE INC. $3,268.90 02/05/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202445051
Principal investigator 1 PFIZER INC. $8,828.00 02/05/2025 Non-covered Recipient Entity
Rheumatology and Pulmonary Clinic
A PHASE 3 MULTICENTER OPENLABEL EXTENSION STUDY TO INVESTIGATE THE LONGTERM SAFETY TOLERABILITY AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228828451
Principal investigator 1 Novartis Pharmaceuticals Corporation $20,086.96 01/30/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC, PLLC
An Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab Infusion in Adults With Giant Cell Arteritis (GCA) or Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1190308042
Principal investigator 1 Eli Lilly and Company $77,689.00 01/28/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187889536
Principal investigator 1 Eli Lilly and Company $2,674.17 01/27/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187889440
Principal investigator 1 Janssen Research & Development, LLC $1,726.00 01/27/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175386283
Principal investigator 1 Amgen Inc. $98,724.00 01/24/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246647309
Principal investigator 1 PFIZER INC. $4,506.86 01/24/2025 Non-covered Recipient Entity
Rheumatology and Pulmonary Clinic
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228831795
Principal investigator 1 Amgen Inc. $7,722.00 01/22/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants with Sjgrens Syndrome With Moderate-to-Severe Symptom State No dispute reported 06/30/2026 1246647300
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $8,841.31 01/21/2025 Non-covered Recipient Entity
Summit Rheumatology - Rheumatology And Pulmonary Clinic
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease-modifying Anti-rheumatic Drugs No dispute reported 06/30/2026 1235993433
Principal investigator 1 Amgen Inc. $394,300.65 01/02/2025 Non-covered Recipient Entity
RHEUMATOLOGY AND PULMONARY CLINIC
A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis No dispute reported 06/30/2026 1246647318